DCTH DELCATH SYSTEMS, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 872912 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.1%
TTM net income YoY455.4%
TTM EPS YoY433.3%
Revenue 3-yr CAGR270.3%
Net income 3-yr CAGR—
Margins
Gross margin87.6%
Operating margin5.2%
Net margin6.1%
FCF margin18.3%
EBITDA margin5.6%
Returns
ROE5.4%
ROA4.9%
ROIC (approx.)5.6%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets10.4%
Debt / equity0.00x
Current ratio10.87x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.46x
Accruals ratio-12.0%
Payout ratio—
Capex / revenue2.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $85.23M | $37.20M | $2.06M | $2.72M | $3.56M |
| Cost of revenue | $11.80M | $6.19M | $635,000 | $686,000 | $671,000 |
| Gross profit | $73.43M | $31.02M | $1.43M | $2.03M | $2.88M |
| R&D expense | $29.25M | $13.87M | $17.50M | $18.58M | $13.78M |
| SG&A expense | $43.53M | $29.55M | $22.11M | $17.30M | $13.64M |
| Operating income | $660,000 | -$12.41M | -$38.18M | -$33.85M | -$24.53M |
| Pretax income | $3.51M | -$26.39M | -$47.68M | -$36.51M | -$25.65M |
| Income tax | $810,000 | $0 | $0 | $0 | $0 |
| Net income | $2.70M | -$26.39M | -$47.68M | -$36.51M | -$25.65M |
| EBITDA | $898,000 | -$12.28M | -$38.05M | -$33.72M | -$24.39M |
| EPS (basic) | 0.08 | -0.93 | -2.94 | -4.12 | -3.59 |
| EPS (diluted) | 0.07 | -0.93 | -2.94 | -4.12 | -3.59 |
| Weighted avg. shares (diluted) | 39.92M | 28.51M | 16.23M | 8.86M | 7.15M |
| Balance sheet | |||||
| Cash & equivalents | $43.45M | $32.41M | $12.65M | $7.67M | $22.80M |
| Short-term investments | $47.58M | $20.82M | $19.81M | $0 | — |
| Receivables | $11.74M | $10.89M | $241,000 | $366,000 | $44,000 |
| Inventory | $10.25M | $6.93M | $3.32M | $2.00M | $1.41M |
| Current assets | $119.53M | $73.76M | $37.16M | $16.16M | $31.15M |
| PP&E, net | $3.17M | $1.79M | $1.35M | $1.42M | $1.35M |
| Total assets | $123.63M | $76.59M | $38.61M | $17.86M | $33.12M |
| Current liabilities | $10.95M | $6.14M | $16.45M | $14.73M | $5.95M |
| Long-term debt | — | $0 | $10.15M | $15.69M | — |
| Total debt | — | $0 | $10.15M | $15.69M | — |
| Total liabilities | $12.41M | $7.84M | $22.84M | $23.72M | $21.17M |
| Shareholders' equity | $111.22M | $68.75M | $15.78M | -$5.86M | $11.95M |
| Net debt | — | -$32.41M | -$2.50M | $8.02M | — |
| Shares outstanding | 34.69M | 33.06M | 22.76M | 10.05M | 7.91M |
| Cash flow statement | |||||
| Operating cash flow | $22.52M | -$18.68M | -$31.25M | -$24.95M | -$22.60M |
| Capital expenditure | $1.55M | $559,000 | $58,000 | $209,000 | $143,000 |
| Free cash flow | $20.97M | -$19.24M | -$31.31M | -$25.16M | -$22.75M |
| Investing cash flow | -$26.59M | -$981,000 | -$19.71M | -$209,000 | -$143,000 |
| Financing cash flow | $15.05M | $39.41M | $51.78M | $10.14M | $20.82M |
| Depreciation & amortization | $238,000 | $134,000 | $128,000 | $132,000 | $146,000 |
| Stock-based compensation | $24.23M | $9.77M | $8.15M | $7.94M | — |
| Share buybacks | $6.00M | $0 | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.